Squarepoint
SLNO

Squarepoint’s Soleno Therapeutics SLNO Stock Holding History

Squarepoint’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,300
Closed -$764K – 4837
2025
Q3 		$764K Buy
+11,300
New +$838K ﹤0.01% 2897
2024
Q4 		– Sell
-16,500
Closed -$833K – 5461
2024
Q3 		$833K Buy
+16,500
New +$790K ﹤0.01% 2746

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Squarepoint's SLNO Position: Q1 2026 in Review

Squarepoint reduced its Soleno Therapeutics (SLNO) stake by 60% in Q1 2026, selling an estimated $11.1M and leaving 185,337 shares worth $6.21M. The position accounts for 0.01% of the portfolio, ranked #1346.

Squarepoint first reported a position in SLNO in Q1 2020 and has held it in 9 quarters since. The position peaked at $21.7M in Q4 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Squarepoint held 185,337 shares of Soleno Therapeutics worth $6.21M as of Q1 2026.
  • Squarepoint sold 283,317 Soleno Therapeutics shares in Q1 2026, an estimated $11.1M.
  • Soleno Therapeutics made up 0.01% of Squarepoint's portfolio in Q1 2026, its #1346 holding.
  • Squarepoint first reported a position in Soleno Therapeutics in Q1 2020 and has held it in 9 quarters since.
  • Squarepoint's Soleno Therapeutics position peaked at $21.7M in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.